Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | USP14 | P54578 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663752 | 0.87 | SLC6A9 (0.42) | GPR119DGAT2CHRM2USP14KDM1A | |
| SCHEMBL5662800 | 0.85 | HRH3 (0.37) | GPR119DGAT2MGLLKDM1AHRH3 | |
| SCHEMBL4827676 | 0.85 | SLC6A9 (0.43) | GPR119DGAT2CHRM2USP14USP30 | |
| SCHEMBL14437322 | 0.85 | SLC6A9 (0.43) | GPR119DGAT2CHRM2USP14USP30 | |
| SCHEMBL5659927 | 0.83 | USP30 (0.39) | GPR119DGAT2MGLLKDM1AHRH3 | |
| SCHEMBL5662257 | 0.80 | FFAR4 (0.37) | KDM1AUSP30 | |
| SCHEMBL4707591 | 0.78 | ACACB (0.41) | GPR119CHRM2CHRM1CHRM3HRH3 | |
| SCHEMBL5662027 | 0.77 | NOTUM (0.44) | GPR119 | |
| SCHEMBL5662757 | 0.76 | CHEK1 (0.34) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL5664969 | 0.76 | GAA (0.40) | CHRM2CHRM1CHRM3SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | claimed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, HSD17B11, CYP11B1 | GPR119 605/4885DGAT2 615/4885CHRM2 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.